Curetis

OpGen Announces Acquisition of Preferred Stock by David Lazar

Retrieved on: 
Monday, March 25, 2024
Common stock, BofA Securities, Doctor of Philosophy, European Investment Bank, EIB, Trustee, Corporate development, Curetis, Corporation

On March 25, 2024, Mr. Lazar paid $200,000 at the initial closing of the transactions in exchange for 200,000 shares of Series E Preferred Stock.

Key Points: 
  • On March 25, 2024, Mr. Lazar paid $200,000 at the initial closing of the transactions in exchange for 200,000 shares of Series E Preferred Stock.
  • Each share of Series E Preferred Stock is convertible into 24 shares of the Company’s common stock (“Common Stock”).
  • The conversion of the Series E Preferred Stock into shares of common stock in excess of applicable statutory and regulatory thresholds, including national stock exchange rules, will be subject to receipt of stockholder approval for the issuance of such shares of Common Stock.
  • We believe the transaction also offers future opportunities for OpGen stockholders to participate in possible future strategic transactions under the leadership of David Lazar and the new members of the board.

OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 10, 2023
Communication, De novo, Classification, Nucleotide, UTI, European Patent Office, Infection, Curetis, Thermo Fisher Scientific, AMR, IP, Sale, Nadine Opgen-Rhein, Single-nucleotide polymorphism, Urinary tract infection, Patent, SNP, Medicine, European Patent Convention, Plasmid, IVD, FDA, Ares, Pneumonia, Video game, Pharmaceutical industry, Q2

ET

Key Points: 
  • ET
    ROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 financial and operating results.
  • Second Quarter 2023 and First Half 2023 Financial Results of OpGen, Inc.
    Total revenue for the second quarter of 2023 was approximately $0.7 million compared to the company’s revenue of approximately $1.0 million in the second quarter of 2022, which was primarily driven by the one-time sale of a pool of Unyvero instrument systems to Menarini in Q2-2022.
  • Total operating expenses decreased in the second quarter of 2023 to approximately $5.9 million compared to approximately $6.2 million for the second quarter of 2022.
  • ET, to review the second quarter 2023 financial results and business activities, but will not be taking any questions.

OpGen’s Subsidiary Curetis and FIND Extend R&D Collaboration Agreement

Retrieved on: 
Thursday, August 3, 2023
Infection, A30, Curetis, Research, AMR, LMIC, Hospital, Medicine, IVD, Blood culture, Nadine Opgen-Rhein, Medical device, Developing country

This extended R&D collaboration now covers the development of an AMR assay and Unyvero A30 cartridge for AMR detection from commonly used blood culture bottles as well as the corresponding software plugin development and full analytical performance evaluation.

Key Points: 
  • This extended R&D collaboration now covers the development of an AMR assay and Unyvero A30 cartridge for AMR detection from commonly used blood culture bottles as well as the corresponding software plugin development and full analytical performance evaluation.
  • Andreas Boos, Chief Technology Officer at Curetis GmbH and program manager for the Unyvero A30 platform development commented, “We are excited to begin working on this new contract and continue our collaboration project.
  • We are focused on making sure diagnostics are accessible to prevent further development of AMR.
  • The Unyvero A30 platform and the AMR test being developed on it has the potential to meet the requirements for use in low- and middle-income countries.

OpGen’s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND

Retrieved on: 
Wednesday, July 19, 2023
NGS, Infection, A30, Curetis, Research, AMR, Global Health Innovative Technology Fund, IP, LMIC, Hospital, Medicine, Nadine Opgen-Rhein, Ares, Medical device, Developing country

Following the delivery of a comprehensive milestone report at the end of the second quarter of 2023, FIND recently confirmed that all requirements have been met successfully.

Key Points: 
  • Following the delivery of a comprehensive milestone report at the end of the second quarter of 2023, FIND recently confirmed that all requirements have been met successfully.
  • This deliverable supports usage of Unyvero A30 test data in resource-constrained settings with minimal infrastructure as often faced in many LMICs.
  • This analysis revealed important differences in the sequences of clinically relevant bacterial strains between those coming from LMICs versus those obtained in Western countries.
  • Dr. Gerd Luedke, Director Innovation, Technology and IP at Curetis GmbH commented, “We are excited to have successfully delivered on all of the milestones from the expanded and extended phase of our collaboration agreement.

OpGen Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, May 15, 2023
Acuitas Therapeutics, Partnership, De novo, Classification, Marketing, UTI, Infection, EST, Thermo Fisher Scientific, Nadine Opgen-Rhein, Urinary tract infection, ARES, Traction, Patent, Medicine, IVD, Diagnosis, Growth, EIB, FDA, News, Pneumonia, Video game, Vaccine, Pharmaceutical industry, Curetis

Management will host an investor call to discuss quarterly results and provide a business update.

Key Points: 
  • Management will host an investor call to discuss quarterly results and provide a business update.
  • Compared to the fourth quarter 2022 revenue of $0.72 million, OpGen achieved a 26% revenue increase in the first quarter of 2023.
  • Total operating expenses decreased in the first quarter of 2023 to $6.0 million compared to $6.3 million for the same quarter in 2022.
  • OpGen’s management will host a conference call today, May 15, 2023 at 4:30 p.m. EST, to review the first quarter 2023 financial results and business activities, as well as answer analyst questions.

OpGen’s Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND

Retrieved on: 
Wednesday, April 26, 2023
Partnership, DNA sequencing, Infection, Research, Temperature, LMIC, Hospital, Medicine, R, Nadine Opgen-Rhein, Medical device, Curetis, Developing country

Following the delivery of a comprehensive milestone report at the end of first quarter of 2023, FIND confirmed that all requirements have been met successfully.

Key Points: 
  • Following the delivery of a comprehensive milestone report at the end of first quarter of 2023, FIND confirmed that all requirements have been met successfully.
  • Under the recently announced expansion of the collaboration, the originally planned Next Generation Sequencing (“NGS”) strain analysis will be complemented with isolates from other sub-Saharan African countries.
  • Multiple Unyvero A30 instrument adaptations were made to optimize for use in the challenging environments of low- and middle- income countries (LMICs).
  • Instrument prototypes have been designed, built and tested for operation in high-dust, extended temperature range and power-out scenarios.

OpGen Subsidiary Curetis Meets Several Key Milestones in FIND Collaboration Project

Retrieved on: 
Tuesday, January 17, 2023
Infection, AMR, DNA, A30, Precision medicine, Nadine Opgen-Rhein, PCR, Patient, Pharmaceutical industry, Developing country, Curetis

This achievement has triggered an undisclosed milestone payment per the terms of the agreement.

Key Points: 
  • This achievement has triggered an undisclosed milestone payment per the terms of the agreement.
  • OpGen’s subsidiary Curetis furthermore provided a report including results from its internal database analysis looking at genetic diversity and resistance profiles in pathogens observed in low and middle income countries (LMICs).
  • Also, a device specification for a prototype cockpit optimized for use with the A30 platform has been defined and agreed upon.
  • Such a next phase collaboration could include clinical studies as well as projects toward certain regulatory filings in various LMICs.”
    Cecilia Ferreyra, Director, FIND AMR Programme remarked that, “the R&D team at OpGen’s subsidiary Curetis has worked to achieve important progress in a short period of time.

OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel

Retrieved on: 
Tuesday, December 13, 2022
Associate, Nadine Opgen-Rhein, Federal, Urinary tract infection, NGS, COVID-19, Diagnosis, Investigational device exemption, Prevalence, FDA, Hospital, Fungus, Precision medicine, Curetis, UTI, De novo, Urinary system, Genetics, Microbiology, Urine, Infection, Medical microbiology, Patient, Communication, Personal Data Privacy and Security Act of 2009, Pharmaceutical industry, Vaccine, Medical device, MD

OpGen’s Unyvero UTI Panel tests for a broad range of bacterial and fungal pathogens as well as antimicrobial resistance markers directly from urine specimens.

Key Points: 
  • OpGen’s Unyvero UTI Panel tests for a broad range of bacterial and fungal pathogens as well as antimicrobial resistance markers directly from urine specimens.
  • The trial was designed to compare the performance of the Unyvero UTI Panel for detecting urinary tract infections (UTI), using clean-catch or catheter related urine samples.
  • These findings are also in line with the interim analysis performed during the first part of the trial.
  • This press release includes statements regarding preliminary analysis and top-line data from OpGen’s clinical trial for its Unyvero Urinary Tract Infection Panel.

OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 10, 2022
GLOBE, UTI, Chairperson, UZ Leuven, Calendar, NMPA, Nadine Opgen-Rhein, Nasdaq, EST, Passport, Research, Curetis, Organization, National Association of Corporate Directors, Director, Sale, Streptococcus pneumoniae, National Association, R, Precision medicine, Solution, Infection, Contract, Company, Organon, General counsel, Corporation, CEO, ARES, FDA, Management, Pharmaceutical industry, Video game

Management will host an investor call to discuss quarterly results and provide a business update.

Key Points: 
  • Management will host an investor call to discuss quarterly results and provide a business update.
  • Third Quarter 2022 Financial Results of OpGen, Inc.
    Total revenue for the third quarter of 2022 was approximately $0.4 million, compared with approximately $1.2 million in the third quarter of 2021.
  • Operating expenses for the third quarter of 2022 were approximately $14.0 million, compared with approximately $6.3 million in the third quarter of 2021.
  • OpGens management will host a conference call today, November 10, at 4:30 p.m. EST, to discuss the third quarter financial results and business activities, as well as answer analyst questions.

OpGen Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2022 and Provides Business Update

Retrieved on: 
Thursday, October 27, 2022
NGS, Infection, Securities Exchange Act of 1934, Security (finance), U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Nasdaq, New York State Department of Health, UZ Leuven, Goal, Hospital, NMPA, Adoption, ARES, Streptococcus pneumoniae, Technology, Nadine Opgen-Rhein, European Investment Bank, COVID-19, GLOBE, Precision medicine, Curetis, Securities Act of 1933, Genetics, Solution, Pharmaceutical industry, MD

Cash as of September 30, 2022 was approximately $10.3 million and, following the successful closing of a financing transaction, was approximately $13.3 million as of October 3, 2022.

Key Points: 
  • Cash as of September 30, 2022 was approximately $10.3 million and, following the successful closing of a financing transaction, was approximately $13.3 million as of October 3, 2022.
  • OpGen, Inc. (Rockville, MD, U.S.A.) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease.
  • This press release includes statements regarding OpGens third quarter 2022 results and the current business of OpGen.
  • We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.